ERBB2 and breast carcinoma: This study identifies CEACAM6 as a robust predictive biomarker for neoadjuvant chemotherapy (NAC) response in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) breast cancer.